Skip to main content
SpringerLink
Log in

Other Clinical Effects of SERMs

  • Chapter
Selective Estrogen Receptor Modulators

  • 545 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Affinito P, Palomba S, Sorrentino C, Di Carlo C, Bifulco G, Arienzo MP, et al. (1999) Effects of postmenopausal hypoestrogenism on skin collagen. Maturitas 33:239–247

    Article  PubMed  CAS  Google Scholar 

  2. Agnusdei D (1999) Clinical efficacy of raloxifene in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 85:43–46

    Article  PubMed  CAS  Google Scholar 

  3. Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Carrido L, et al. (2004) Predictors of hot flushes in postmenopausal women who receive raloxifene therapy. Am J Obstet Gynecol 191:1979–1988

    Article  PubMed  CAS  Google Scholar 

  4. Alvaro D, Alpini G, Onori P, Perego L, Svegliata Baroni G, Franchitto A, et al. (2000) Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology 119:1681–1691

    Article  PubMed  CAS  Google Scholar 

  5. Andersson B, Johannsson G, Holm G, Bengtsson BA, Sashegyi A, Pavo I, Mason T, Anderson PW (2002) Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. J Clin Endocrinol Metab 87:122–128

    Article  PubMed  Google Scholar 

  6. Bergman A, Karram M, Bahatia N (1990) Changes in urethral cytology following estrogen administration. Gynecol Obstet Invest 29:211–213

    Article  PubMed  CAS  Google Scholar 

  7. Bernardi F, Pluchino N, Stomati M, Pieri M, Genazzani AR (2003) CNS: sex steroids and SERMSs. Ann NY Acad Sci 997:378–88

    Article  PubMed  CAS  Google Scholar 

  8. Bishai R, Arbour L, Lyons C, Koren G (1999) Intrauterine exposure to clomiphene and neonatal persistent hyperplastic primary vitreous. Teratology 60:143–145

    Article  PubMed  CAS  Google Scholar 

  9. Bradbury BD, Lash TL, Kaye JA, Jick SS (2004) Tamoxifen and cataracts: a null association. Breast Cancer Res Treat 87:189–196

    Article  PubMed  CAS  Google Scholar 

  10. Casper RF, McPherson R, Ste-Marie LG (1998) The Canadian Consensus Conference on menopause and osteoporosis. J Soc Obstet Gynaecol Can 20:1243–1272

    Google Scholar 

  11. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L (2000) Uterine effects of three-year raloxifene therapy in postmenopausal women under age 60. Obstet Gynecol 95:104–110

    Article  PubMed  CAS  Google Scholar 

  12. Creamer P, Lim K, George E, Dieppe P (1994) Acute inflammatory polyarthritis in association with tamoxifen. Br J Rheumatol 33:998

    Google Scholar 

  13. Davies GC, Huster WJ, Lu Y, Plouffe L, Lakshmanan M (1999) Adverse events reported by postmenopausal women in controlled trialswiths raloxifene. Obstet Gynecol 93:558–565

    Article  PubMed  CAS  Google Scholar 

  14. Duntas LH, Mantzou E, Koutras DA (2001) Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status. Thyroid 11:779–782

    Article  PubMed  CAS  Google Scholar 

  15. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ (2004) Estrogen-and tamoxifen-associated effects on brain structure and function. Neuro Image 21:364–371

    PubMed  Google Scholar 

  16. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22:4261–4271

    Article  PubMed  CAS  Google Scholar 

  17. Gerard B, Bleiberg H (2004) Treatment of hepatocarcinoma. Curr Oncol Rep 6:184–191

    PubMed  Google Scholar 

  18. Gerner EW (1989) Ocular toxicity of tamoxifen. Ann Ophthalmol 21:420–423

    PubMed  CAS  Google Scholar 

  19. Goldstein SR (2002) An update on non-uterine gynaecological effects on raloxifene. Eur J Cancer 38(Suppl 6):S65–S66

    Article  PubMed  Google Scholar 

  20. Goldstein SR, Nanavati N (2002) Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 187:521–527

    Article  PubMed  CAS  Google Scholar 

  21. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK (2000) A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 95:95–103

    Article  PubMed  CAS  Google Scholar 

  22. Goldstein SR, Neven P, Zhour L, Taylor YL, Ciaccia AV, Plouffe L Jr (2001) Raloxifene effects on frequency of surgery for pelvic floor relaxation. Obstet Gynecol 98:91–96

    Article  PubMed  CAS  Google Scholar 

  23. Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, et al. (1998) Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 126:338

    Article  Google Scholar 

  24. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T (2001) Post-menopausal hormones and incontinence: the heart and estrogen/progestin replacement study. Obstet Gynecol 97:116–120

    Article  PubMed  CAS  Google Scholar 

  25. Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A, Cummings S, Multiple Outcomes of Raloxifene Evaluation Investigators (2004) Safety and adverse effects associated with raloxifene: multiple outcome of raloxifene evaluation. Obstet Gynecol 104:837–844

    PubMed  CAS  Google Scholar 

  26. Haskell SG, Richardson E (2004) The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial. Conn Med 68:355–358

    PubMed  Google Scholar 

  27. Hendrix LS, McNeeley SG (2001) Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium. Ann NY Acad Sci 949:243–250

    Article  PubMed  CAS  Google Scholar 

  28. Hsu S, Cheng WCh, Jang MW, Tsai KS (2001) Effects of long-term use of raloxifene, a selective estrogen receptor modulator, on thyroid function test profiles. Clin Chem 47:1865–1867

    PubMed  CAS  Google Scholar 

  29. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S (2004) Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pil study. Psychooncology 13:61–66

    Article  PubMed  Google Scholar 

  30. Lacreuse A, Wilson ME, Herndon JG (2002) Estradiol, but not raloxifene, improves aspects of spatial working memory in aged ovariectomized rhesus monkeys. Neurobiol Ag 23:589–600

    Article  CAS  Google Scholar 

  31. Martino S, Cauley JA, Barrtt-Connor E, Powles TJ, Mershon J, Disch D, et al. (2004) Continuing outcomes relevant to Evista: Breast cancer incidence in postemenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751–1761

    Article  PubMed  CAS  Google Scholar 

  32. Miller CP (2002) SERMSs: evolutionary chemistry, revolutionary biology. Curr Pharm Des 8:2089–2111

    Article  PubMed  CAS  Google Scholar 

  33. Modugno F, Ness RB, Exing S, Cauley JA (2003) Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis. Obstet Gynecol 101:353–361

    Article  PubMed  CAS  Google Scholar 

  34. Morales L, Neven P, Timmerman D, Christiaens MR, Vergote I, Van Limbergen E, et al. (2004) Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 15:753–760

    Article  PubMed  CAS  Google Scholar 

  35. Mourits MJ, Bockermann I, de Vries EG, van der Zee AG, ten Hoor KA, van der Graaf WT, Sluiter WJ, Willemse PH (2002) Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 86:1546–1550

    Article  PubMed  CAS  Google Scholar 

  36. Muchmore DB (2000) Raloxifene: a selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist 5:388–392

    Article  PubMed  CAS  Google Scholar 

  37. Natale V, Albertazzi P, Missiroli N, Pedrini D, Salgarello M (2004) Effects of raloxifene on mood, sleep, libido and cognitive function in postmenopausal healthy women: a pilot study. Maturitas 48:59–63

    Article  PubMed  CAS  Google Scholar 

  38. Neele SJM, Evertz R, Genazzani AR, Luisi M, Netelenbos C (2002) Raloxifene treatment increases plasma levels of β-endorphin in postmenopausal women: a randomized, placebo-controlled study. Fertil Steril 77:1110–1117

    Article  PubMed  Google Scholar 

  39. Nickelsen T, Lufkin EG, Riggs BL, Cox DA, Crook TH (1999) Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 24:115–128

    Article  PubMed  CAS  Google Scholar 

  40. Nowak A, Findlay M, Culjak G, Stockler M (2004) Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev 3:CD001024

    Google Scholar 

  41. Paganini-Hill A, Clark LJ (2000) Eye problems in breast cáncer patients treated with tamoxifen. Breast Cancer Res Treat 60:167–172

    Article  PubMed  CAS  Google Scholar 

  42. Palomba S, Orio F Jr, Russo T, Falbo A, Amati A, Zullo F (2004) Gonadotropin-releasing hormone agonist with or without raloxifene effects on cognition, mood, and quality of life. Fertil Steril 82:480–482

    Article  PubMed  CAS  Google Scholar 

  43. Reddy A, Prince M, James OF, Jain S, Bassendine MF (2004) Tamoxifen: anovel treatment for primary biliary cirrhosis? Liver Int 24:194–197

    Article  PubMed  CAS  Google Scholar 

  44. Rekers H, Drogendijk AC, Valkenburg HA, Riphagen F (1992) The menopause, urinary incontinence and other symptoms of the genito-urinary tract. Maturitas 15:101–111

    Article  PubMed  CAS  Google Scholar 

  45. Robinson D, Cardozo LD (2003) The role of estrogens in female lower urinary tract dysfunction. Urology 62:45–51

    Article  PubMed  Google Scholar 

  46. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O (2003) Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 10:433–439

    Article  PubMed  Google Scholar 

  47. Shand B, Gilchrist N, Blackwell T, March R (2002) The hemorheological effects of raloxifene in postmenopausal women with osteoporosis. Results of a 3-year placebo-controlled clinical trial. Clin Hemorheol Microcir 26:249–255

    CAS  Google Scholar 

  48. Sherwin BB (2002) Estrogen and cognitive aging in women. Trends Pharmacol Sci 23:527–534

    Article  PubMed  CAS  Google Scholar 

  49. Shilling V, Jenkins V, Fallowfield L, Howell A (2001) The effects of oestrogens and anti-oestrogens on cognition. Breast 10:484–491

    Article  PubMed  CAS  Google Scholar 

  50. Shively CA, Bethea CL (2004) Cognition, mood disorders, and sex hormones. ILAR J 45:189–199

    PubMed  CAS  Google Scholar 

  51. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. and WHIMS Investigators (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 289:2651–2662

    Article  CAS  Google Scholar 

  52. Stevens HP, Ostlere LS, Black CM, Jacobs HS, Rustin MH (1993) Cyclical psoriatic arthritis responding to anti-oestrogen therapy. Br J Dermatol 129:458–460

    Article  PubMed  CAS  Google Scholar 

  53. Tonelli F, Ficari F, Valanzano R, Brandi ML (2003) Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumore 89:391–396

    CAS  Google Scholar 

  54. Tsai CL, Liu TK (1992) Inhibition of estradiol-induced early osteoarthritic changes by tamoxifen. Life Sci 50:1943–1951

    Article  PubMed  CAS  Google Scholar 

  55. Utian WH, Janata JW, Barbier S, Rosen AS, Mayer MH, Taylor MB (2004) Effect of raloxifene on quality of life: a prospective study using the Utian Quality of Life (UQOL) scale. Menopause 11:275–280

    Article  PubMed  Google Scholar 

  56. Vickers SM, Jhala NC, Ahn EY, McDonald JM, Pan G, Bland KI (2002) Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma). Ann Surg 235:872–878

    Article  PubMed  Google Scholar 

  57. Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, Nickelsen T, Multiple Outcomes of Raloxifene Evaluation Investigators (2001) Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344:1207–1213

    Article  PubMed  CAS  Google Scholar 

  58. Zec RF, Trivedi MA (2002) The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol Rev 12:65–109

    Article  PubMed  Google Scholar 

  59. Zhang JJ, Jacob TJ, Valverde MA, Hardy SP, Mintening GM, Supúlveda FV, et al. (1994) Tamoxifen blocks chloride channels: a possible mechanism for cataract formation. J Clin Invest 94:1690–1697

    Article  PubMed  CAS  Google Scholar 

  60. Zhang JJ, Jacob TJ, Hardy SP, Higgins CF, Valverde MA (1995) Lens opacification by antioestrogens: tamoxifen vs ICI 182,780. Br J Pharmacol 115:1347–1348

    PubMed  CAS  Google Scholar 

  61. Zidan J, Rubenstein W (1999) Effect of adjuvant tamoxifen therapy on thyroid function in postmenopausal women with breast cancer. Oncology 56:43–45

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of Obstetrics and Gynecology, San Juan University Hospital, Alicante, Spain

    P. Acién, F. Quereda & M. I. Acién

  2. Dept/Division of Gynecology School of Medicine, “Miguel Hernńdez” University Campus of San Juan, Alicante, Spain

    P. Acién, F. Quereda & M. I. Acién

Authors
  1. P. Acién
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Quereda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. I. Acién
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics Obstetrics and Gynecology School of Medicine, University of Valencia, Valencia, Spain

    Antonio Cano Sanchez

  2. Servei d’Obstetricia i Ginecologia, Hospital de la Santa Creu i Sant Pau, C/ Sant Antoni M. Claret 167, 08025, Barcelona

    Joaquim Calaf i Alsina

  3. Department of Obstetrics and Gynaecology, Hospital Universitario Virgen Macarena, School of Medicine University of Sevilla, Sevilla, Spain

    José-Luis Dueñas-Díez

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Acién, P., Quereda, F., Acién, M.I. (2006). Other Clinical Effects of SERMs. In: Sanchez, A.C., Calaf i Alsina, J., Dueñas-Díez, JL. (eds) Selective Estrogen Receptor Modulators. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-34742-9_13

Download citation

  • DOI: https://doi.org/10.1007/3-540-34742-9_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-24227-7

  • Online ISBN: 978-3-540-34742-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation